论文部分内容阅读
目的 依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的长期随访研究.方法 选取郑州市第十人民医院2010年4月至201 1年4月80例慢性肾炎伴高血压患者为研究对象,将患者抽签随机分为观察组与对照组,每组40例.对照组给予辛伐他汀治疗,观察组在对照组的基础上另行依折麦布干预,随访1年,比较两组甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等血脂水平,血尿素氮、肌酐等肾功能指标,收缩压、舒张压,心血管事件发生率及不良反应发生率.结果 观察组治疗后TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,有统计学意义(P＜0.05).观察组血尿素氮(9.24±5.13) mmol/L、肌酐(212.69 ±68.53) μmol/L均低于对照组,有统计学意义(P＜0.05).观察组收缩压、舒张压均低于对照组,有统计学意义(P＜0.05).观察组心血管事件发生率22.50％低于对照组45.00％,有统计学意义(P＜0.05).两组不良反应发生率比较无统计学意义(P＞0.05).结论 依折麦布联合辛伐他汀治疗慢性肾炎伴高血压,可有效调节患者血脂水平,降低血压,改善患者肾功能,远期治疗效果较好,安全性高,具有较好的临床应用价值.“,”Objective To study the cardiac and renal protective effect of ezetimibe combined with simvastatin in patients with chronic nephritis complicated with hypertension.Methods Totally 80 patients with chronic nephritis complicated with hypertension who were admitted into our hospital between April 2010 and April 2011 were selected as the study objects.They were randomized into observation group and control group,40 cases in each group.The control group was treated with simvastatin while the observation group,based on the treatment in the control group,was given ezetimibe intervention.After 1 year of follow-up,the blood lipid levels [triglyceride (TG),total cholesterol (TC),high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C) etc.],renal function indexes (blood urea nitrogen,creatinine),systolic blood pressure,diastolic blood pressure,incidence rates of cardiovascular event and adverse reactions were compared between the two groups.Results After treatment,the levels of TC,TG and LDL-C in the observation group were lower than those in the control group while HDL-C level was higher than that in the control group (P ＜ 0.05).The blood urea nitrogen [(9.24 ± 5.13) mmol/L] and creatinine [(212.69 ± 68.53)μmol/L] in observation group were lower than those in the control group (P ＜ 0.05).The systolic blood pressure and diastolic blood pressure of observation group were lower than those of the control group (P ＜ 0.05).The incidence rate of cardiovascular events in the observation group (22.50％) was lower than that in the control group (45.00％) (P ＜ 0.05).The difference in the incidence of adverse reactions between the two groups was not statistically significant (P ＞ 0.05).Conclusion The application of ezetimibe combined with simvastatin in the treatment of chronic nephritis with hypertension can effectively regulate the blood lipid levels,lower blood pressure,and improve renal function in patients.The long-term curative effect is relative better,and safety is high.The treatment is of good clinical application value.